Overview

  • Product name
    Bisdemethoxycurcumin
  • Description
    Apoptotic anticancer, anti-inflammatory and antioxidant curcuminoid
  • Alternative names
    • BDMC
    • Bisdesmethoxycurcumin
    • Curcumin III
    • Didemethoxycurcumin
  • Biological description
    Apoptotic anticancer, anti-inflammatory and antioxidant curcuminoid. Inhibits wnt activity through activation of WIF-1. Induces demethylation through DNA methyltransferase 1 inhibition. Potent and competitive aldo-keto reductase inhibitor (Ki = 22 nM).
  • Purity
    > 98%

Properties

Applications

Our Abpromise guarantee covers the use of ab120976 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies Use at an assay dependent concentration.

Images

  • ab18210 staining Bcl2 in HeLa cells treated with bisdemethoxycurcumin (ab120976), by ICC/IF. Decrease of Bcl2 expression correlates with increased concentration of bisdemethoxycurcumin, as described in literature.
    The cells were incubated at 37°C for 6 hours in media containing different concentrations of ab120976 (bisdemethoxycurcumin) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab18209 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

References

This product has been referenced in:
  • Liu YL  et al. The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets 11:1098-110 (2011). Read more (PubMed: 21933103) »
  • Kim AN  et al. Up-regulation of heme oxygenase-1 expression through CaMKII-ERK1/2-Nrf2 signaling mediates the anti-inflammatory effect of bisdemethoxycurcumin in LPS-stimulated macrophages. Free Radic Biol Med 49:323-31 (2010). Read more (PubMed: 20430097) »
  • Matsunaga T  et al. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis. Biochem Biophys Res Commun 389:128-32 (2009). Read more (PubMed: 19706287) »

See 0 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab120976.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up